These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35681606)

  • 21. Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors.
    Brocco D; Lanuti P; Pieragostino D; Cufaro MC; Simeone P; Bologna G; Di Marino P; De Tursi M; Grassadonia A; Irtelli L; De Lellis L; Veschi S; Florio R; Federici L; Marchisio M; Miscia S; Cama A; Tinari N; Del Boccio P
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma.
    Ao H; Xin Z; Jian Z
    Biomark Res; 2021 Dec; 9(1):91. PubMed ID: 34930486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.
    Yang F; Wang JF; Wang Y; Liu B; Molina JR
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
    Kloten V; Lampignano R; Krahn T; Schlange T
    Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deleterious
    Cui Y; Liu X; Wu Y; Liang X; Dai J; Zhang Z; Guo R
    Front Oncol; 2022; 12():798401. PubMed ID: 35359393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapeutic Advances for NSCLC.
    Massafra M; Passalacqua MI; Gebbia V; Macrì P; Lazzari C; Gregorc V; Buda C; Altavilla G; Santarpia M
    Biologics; 2021; 15():399-417. PubMed ID: 34675481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.
    Chen Y; Li X; Liu G; Chen S; Xu M; Song L; Wang Y
    Front Oncol; 2020; 10():1706. PubMed ID: 33014846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients.
    Gkountakos A; Delfino P; Lawlor RT; Scarpa A; Corbo V; Bria E
    Ther Adv Med Oncol; 2021; 13():17588359211006947. PubMed ID: 34104224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead.
    Hita-Millan J; Carracedo A; Fernandez-Rozadilla C
    J Pers Med; 2021 Sep; 11(10):. PubMed ID: 34683113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
    Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
    Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
    Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
    ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
    Brueckl WM; Ficker JH; Zeitler G
    BMC Cancer; 2020 Dec; 20(1):1185. PubMed ID: 33272262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
    Buder-Bakhaya K; Hassel JC
    Front Immunol; 2018; 9():1474. PubMed ID: 30002656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.